CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF...Licence and Development Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • England
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF...License Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • California
NOW, THEREFORE, the Parties, in consideration of the mutual covenants and undertakings contained herein and for other good and valuable consideration including the share subscription by UCLB (for and on behalf of both UCLB and UCLA), intending to be legally bound, HEREBY AGREE as follows:
DATED JANUARY 19, 2018 NEW CONNECT INVESTMENTS LIMITED AND ORCHARD THERAPEUTICS LIMITED LEASE OF 2nd and 3rd FLOOR, 108 CANNON STREET, LONDON Lewis Silkin LLP Clifford’s Inn London EC4A 1BL (Ref: EMH8296/112671.14)Lease Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances)
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING...Research and Development Collaboration and License Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • England
This RESEARCH, DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of October 15th, 2010 (the “Effective Date”) by and between (a) Fondazione Telethon, having a registered office at via Carlo Spinola, 16, 00154, Rome, Italy (“F. Telethon”), and Fondazione Centro San Raffaele del Monte Tabor, having a registered office at Via Olgettina 60 20132 Milano (“F. San Raffaele”), each entity, a not-for-profit corporation incorporated under the laws of Italy, (F. Telethon and F. San Raffaele are hereinafter referred to jointly as “TELETHON-HSR”) on the one hand; and, (b) on the other hand, Glaxo Group Limited, a company incorporated under the laws of England and Wales with registered number 00305979, whose registered office is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). TELETHON-HSR and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
